Entasis Therapeutics
$2.719876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.08 (-2.92%) Today
+$0.05 (+1.88%) As of 1:00 AM UTC after-hours
Why Robinhood?
You can buy or sell ETTX and other stocks, options, and ETFs commission-free!
About ETTX
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. The listed name for ETTX is Entasis Therapeutics Holdings Inc. Common Stock.
CEO
Manoussos Perros
Employees
47
Headquarters
Waltham, Massachusetts
Founded
2018
Market Cap
100.91M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
337.57K
High Today
$2.90
Low Today
$2.62
Open Price
$2.81
Volume
263.40K
52 Week High
$5.64
52 Week Low
$1.58
Analyst Ratings
100%
of 7 ratings
Buy
100%
Hold
0%
Sell
0%
ETTX Earnings
-$1.15
-$0.77
-$0.38
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 26, Pre-Market